Newborn screening for mucopolysaccharidoses: Opinions of patients and their families

Clinical Genetics

Volumn 71, Issue 5, 2007, Pages 446-450

  Hayes, I M ^a   Collins, V ^a,b   Sahhar, M ^a   Wraith, J E ^c   Delatycki, Martin B ^a,d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Lysosomal storage disorders; Mucopolysaccharidoses; Newborn screening; Opinions; Questionnaire

Indexed keywords

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; AUSTRALIA; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DISTRESS SYNDROME; EARLY DIAGNOSIS; EARLY INTERVENTION; FEMALE; HUMAN; MALE; MUCOPOLYSACCHARIDOSIS; NEWBORN SCREENING; PATIENT ATTITUDE; PRIORITY JOURNAL; PUBLIC OPINION; QUESTIONNAIRE; SOCIAL PSYCHOLOGY; UNITED STATES;

AUSTRALIA; FAMILY; HUMANS; INFANT, NEWBORN; MUCOPOLYSACCHARIDOSES; NEONATAL SCREENING; QUESTIONNAIRES; UNITED STATES;

EID: 34248344253     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2007.00783.x     Document Type: Article

References (23)

1. Bradley D, Parsons E, Clark A. Experience of screening newborns for Duchenne muscular dystrophy in Wales. Br Med J 1993: 306: 357-360.
2. Fearing MK, Levy HL. Expanded newborn screening using tandem mass spectrometry. Adv Pediatr 2003: 50: 81-111.
3. Meikle PJ, Grasby DJ, Dean CJ et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab 2006: 88 (4): 307-314.
4. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999: 281 (3): 249-354.
5. Pastores GM, Barnett NL. Current and emerging therapies for the lysosomal storage disorders. Expert Opin Emerg Drugs 2005: 10 (4): 891-902.
6. Muenzer J, Wraith JE, Beck M et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006: 8 (8): 465-473.
7. Kakkis ED. Enzyme replacement therapy for the mucopolysaccharide storage disorders. Expert Opin Investig Drugs 2002: 11 (5): 675-685.
8. Harmatz P, Giugliani R, Schwartz I et al. Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006: 148 (4): 533-539.
9. Wang D, Eadala B, Sadilek M et al. Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin Chem 2005: 51 (5): 898-900.
10. Wang D, Wood T, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem 2007: 53 (1): 137-140.
11. Hildes E, Jacobs HK, Cameron A et al. Impact of genetic counselling after neonatal screening for Duchenne muscular dystrophy. J Med Genet 1993: 30 (8): 670-674.
12. Parsons EP, Clarke AJ, Hood K, Lycett E, Bradley DM. Newborn screening for Duchenne muscular dystrophy: A psychosocial study. Arch Dis Child Fetal Neonatal Ed 2002: 86 (2): F91-F95.
13. Campbell E, Ross LF. Parental attitudes regarding newborn screening of PKU and DMD. Am J Med Genet 2003: 120A (2): 209-214.
14. Parsons EP, Bradley DM. Psychosocial issues in newborn screening for cystic fibrosis. Paediatr Respir Rev 2003: 4 (4): 285-292.
15. Wilson J, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization, 1968.
16. Watson M, Lloyd-Puryear MA, Mann M et al. Newborn screening: Toward a uniform screening panel and system. Genet Med 2006: 8 (Suppl.): 12S-252S.
17. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004: 27 (3): 385-410.
18. Wraith JE. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties. J Inherit Metab Dis 2001: 24 (2): 245-250.
19. Wraith JE, Clarke LA, Beck M et al. Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004: 144 (5): 581-588.
20. Kakkis ED, Muenzer J, Tiller GE et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001: 344 (3): 182-188.
21. Al-Jader LN, Goodchild MC, Ryley HC, Harper PS. Attitudes of parents of cystic fibrosis children towards neonatal screening and antenatal diagnosis. Clin Genet 1990: 38 (6): 460-465.
22. Merelle ME, Huisman J, Alderden-van der Vecht A et al. Early versus late diagnosis: Psychological impact on parents of children with cystic fibrosis. Pediatrics 2003: 111 (2): 346-350.
23. Boland C, Thompson NL. Effects of newborn screening of cystic fibrosis on reported maternal behaviour. Arch Dis Child 1990: 65: 1240-1244.